List of largest pharmaceutical companies by revenue
The following is a list of the top independent pharmaceutical & biotechnology companies ranked by their revenue generated ($10 billion) in the respective financial year, it does not include biotechnology companies that are now owned by, or part of, larger pharmaceutical groups.
The change is the companies relative position in this list, compared to their relative position in the prior year; i.e., an increase would be moving closer to rank 1 and vice versa. Green cells indicate years where revenue increased compared to the previous year, red cells indicate those years where there has been a decrease.
Top pharmaceutical companies with revenue greater than $10 billion
Rank | Chg | Company | 2018 USD billions |
2017 USD billions |
2016 USD billions |
2015 USD billions |
2014 USD billions |
2013 USD billions |
2012 USD billions |
2011 USD billions |
---|---|---|---|---|---|---|---|---|---|---|
1 | NYSE: JNJ |
40.81 (Q2)[1] | 76.50[2] | 71.89[3] | 70.10[4] | 74.30[5] | 71.31[6] | 67.20[7] | 65.00[8] | |
2 | OTCQX: RHHBY |
28.30 (Q2)[9] | 57.37[10] | 50.11[11] | 47.70[12] | 49.86[13] | 48.53[14] | 47.80[15] | 45.21[16] | |
3 | NYSE: PFE |
26.37 (Q2)[17] | 52.54[18] | 52.82[19] | 48.85[20] | 49.61[21] | 51.58[22] | 58.99[23] | 65.26[24] | |
4 | NYSE: NVS |
25.85 (Q2)[25] | 49.11[26] | 48.52[27] | 49.41[28] | 58.00[29] | 57.36[30] | 56.67[31] | 58.57[32] | |
5 | FWB: BAYN |
21.80 (Q2) | 27.76[33] | 25.27[34] | 24.09[35] | 25.47[36] | 24.17[37] | 24.30[38] | 23.11[39] | |
6 | NYSE: MRK |
20.51 (Q2)[40] | 40.10[41] | 39.80[42] | 39.50[43] | 42.24[44] | 44.03[45] | 47.27[46] | 48.05[47] | |
7 | LSE: GSK |
19.74 (Q2)[48] | 42.05[49] | 34.79[50] | 29.84[51] | 37.96[52] | 41.61[53] | 39.93[54] | 41.39[55] | |
8 | NYSE: SNY |
18.65 (Q2)[56] | 42.91[57] | 36.57[58] | 36.73[59] | 43.07[60] | 42.08[61] | 46.41[62] | 44.34[63] | |
9 | NYSE: ABBV |
16.21 (Q2)[64] | 28.22[65] | 25.56[66] | 22.82[67] | 19.96[68] | 18.79[69] | – | – | |
10 | NASDAQ: ABT |
15.16 (Q2)[70] | 27.39[71] | 20.85[72] | 20.41[73] | 20.25[74] | 21.85[75] | 39.87[76] | 38.85[77] | |
11 | NYSE: LLY |
14.08 (Q2)[78] | 22.90[79] | 21.22[80] | 20.00[81] | 19.62[82] | 23.11[83] | 22.60[84] | 24.29[85] | |
12 | NASDAQ: AMGN |
11.61 (Q2)[86] | 22.80[87] | 22.99[88] | 21.66[89] | 20.06[90] | 18.68[91] | 17.30[92] | 15.58[93] | |
13 | NASDAQ: BMY |
10.90 (Q2)[94] | 20.80[95] | 19.43[96] | 16.56[97] | 15.88[98] | 16.39[99] | 17.62[100] | 21.24[101] | |
14 | NASDAQ: GILD |
10.54 (Q2)[102] | 25.70[103] | 30.39[104] | 32.15[105] | 24.47[106] | 10.80[107] | 9.70[108] | 8.39[109] | |
15 | LSE: AZN |
10.33 (Q2)[110] | 22.47[111] | 23.00[112] | 24.71[113] | 26.10[114] | 25.71[115] | 27.97[116] | 33.59[117] | |
16 | NASDAQ: TEVA |
9.77 (Q2)[118] | 22.40[119] | 21.90[120] | 20.00[121] | 20.27[122] | 20.31[123] | 18.31[124] | 16.12[125] | |
17 | Private |
21.67[126] | 17.54[127] | 16.41[127] | 17.70[127] | 18.68[127] | 18.89[127] | 18.34[127] | ||
18 | ETR: MRK |
8.83(Q2)[128] | 18.70[129] | 16.62[130] | 14.25[131] | 15.29[132] | 14.73[133] | 14.36[134] | 14.31[135] | |
19 | NYSE: NVO |
8.41 (Q2)[136] | 18.77[137] | 16.61[138] | 16.06[139] | 15.83[140] | 14.88[141] | 13.48[142] | 11.56[143] | |
20 | NYSE: AGN |
7.79 (Q2)[144] | 15.94[145] | 14.57[145] | 15.07[145] | 12.88[146] | 8.68[147] | 5.91[148] | 4.58[149] | |
20 | TYO: 4502 |
4.05 (Q1) | 16.70[150] | 15.96 | 14.93 | 16.84 | 17.36 | 18.91 | 17.80 | |
21 | NASDAQ: SHPG |
7.58 (Q2)[151] | 14.40[152] | 11.40[153] | 6.42[154] | 6.00[155] | 4.76[156] | 4.68[157] | 3.50[158] | |
22 | NASDAQ: CELG |
7.34 (Q2)[159] | 13.00 | 11.23 | 9.26 | 7.67 | 6.49 | 5.51 | 4.84 | |
23 | NASDAQ: BIIB |
6.53 (Q2)[160] | 12.30[161] | 11.40[162] | 10.80[163] | 9.70[164] | 6.90[165] | 5.50[166] | 5.00[167] |
See also
References
- ↑ Johnson, Johnson &. "Johnson & Johnson Reports 2018 First-Quarter Results:". www.prnewswire.com.
- ↑ "Johnson & Johnson Reports 2017 Fourth-Quarter Results: - Johnson & Johnson". www.jnj.com.
- ↑ "Johnson & Johnson Reports 2016 Fourth-Quarter Results - Johnson & Johnson". www.jnj.com.
- ↑ "Johnson & Johnson Reports 2015 Fourth-Quarter Results:".
- ↑ "Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com.
- ↑ "Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com.
- ↑ "Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:".
- ↑ "Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:".
- ↑ https://www.fiercepharma.com/pharma/roche-ups-2018-guidance-again-as-ocrevus-steams-pass-blockbuster-threshold
- ↑ "Roche reports good results in 2017". www.roche.com.
- ↑ https://www.roche.com/dam/jcr:ee2f197f-5487-4629-9e28-66b77c9cbbab/en/ar16e.pdf
- ↑ https://www.roche.com/dam/jcr:9b36e11d-495c-42f5-b757-e80c4e88d793/en/gb15e.pdf
- ↑ https://www.roche.com/dam/jcr:880b44a1-3fd6-4e66-bf10-f4af1e724d4d/en/gb14e.pdf
- ↑ https://www.roche.com/dam/jcr:64fd6b2d-1a76-467f-badd-ab94b85b6d70/en/gb13e.pdf
- ↑ https://www.roche.com/dam/jcr:3e048249-e3ce-4969-a77e-cc90d8f3fa73/en/gb12e.pdf
- ↑ https://www.roche.com/dam/jcr:52174b39-feab-4210-82f6-9b8786a69ecf/en/gb11e.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2018/q2/Q2-2018-PFE-Earnings-Release.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2017/Q4_2017_PFE_Earnings_Release.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2016/2016-financial-report.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2015/2015_Pfizer_Financial_Report.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2014/2014_Pfizer_Financial_Report.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2013/FinancialReport2013.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2012/financial2012.pdf
- ↑ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2011/financial2011.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/q2-2018-media-release-en.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2017-en.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2016-en.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2015-en.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2014-en.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2013-en.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2012-en.pdf
- ↑ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2011-en.pdf
- ↑ http://www.annualreport2017.bayer.com/servicepages/downloads/files/bayer_ar17_entire.pdf
- ↑ http://www.annualreport2016.bayer.com/servicepages/downloads/files/bayer_ar16_entire.pdf
- ↑ http://www.annualreport2015.bayer.com/servicepages/downloads/files/entire_bayer_ar15.pdf
- ↑ http://www.annualreport2014.bayer.com/en/bayer-annual-report-augmented-version-2014.pdfx
- ↑ https://www.bayer.com/en/ar-2013.pdfx
- ↑ https://www.bayer.com/en/ar-2012.pdfx
- ↑ https://www.bayer.com/en/ar-2011.pdfx
- ↑ http://investors.merck.com/news/press-release-details/2018/Merck-Announces-Second-Quarter-2018-Financial-Results/default.aspx
- ↑ LaVito, Angelica (2 February 2018). "Merck posts mixed fourth-quarter results as Keytruda sales skyrocket".
- ↑ http://s21.q4cdn.com/488056881/files/doc_financials/2017/Q4/merck-q4-10k.pdf
- ↑ http://s21.q4cdn.com/488056881/files/doc_financials/2015/annual/MRK_2015_Form_10-K_FINAL_r879.pdf
- ↑ http://s21.q4cdn.com/488056881/files/doc_financials/2014/annual/2014-Form-10-K_FINAL_022715.pdf
- ↑ http://s21.q4cdn.com/488056881/files/doc_financials/2013/annual/MRK_2013_Form_10_K_FINAL_022714.pdf
- ↑ http://s21.q4cdn.com/488056881/files/doc_financials/2012/annual/MRK_form_10_k_2012.pdf
- ↑ http://s21.q4cdn.com/488056881/files/doc_financials/2011/annual/form-10-k-2011.pdf
- ↑ https://www.gsk.com/media/5011/q2-2018-results-and-rd-update-announcement.pdf
- ↑ https://www.gsk.com/media/4629/fy-2017-results-announcement.pdf
- ↑ https://www.gsk.com/media/3609/annual-report-2016.pdf
- ↑ https://www.gsk.com/media/2718/gsk-annual-report-2016.pdf
- ↑ https://www.gsk.com/media/2710/gsk-annual-report-2014-interactive.pdf
- ↑ https://www.gsk.com/media/2701/annual-report-2013-interactive.pdf
- ↑ https://www.gsk.com/media/2694/annual-report-2012.pdf
- ↑ https://www.gsk.com/media/2696/annual-report-2011.pdf
- ↑ http://mediaroom.sanofi.com/first-quarter-2018-business-eps1-up-1-4-at-cer/
- ↑ https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/en/investors/docs/press-releases/Press_release_Q4_FY_2017.pdf
- ↑ https://en.sanofi.com/Images/49288_20-F_2016.pdf
- ↑ https://en.sanofi.com/Images/45889_Sanofi_20-F_2015_V2.pdf
- ↑ https://en.sanofi.com/Images/38473_Sanofi_20-F_2014.pdf
- ↑ https://en.sanofi.com/Images/35795_20F_SANOFI_2013.pdf
- ↑ https://en.sanofi.com/Images/31972_20-F_2012_V2.pdf
- ↑ https://en.sanofi.com/Images/29804_20F_2011.pdf
- ↑ https://news.abbvie.com/news/abbvie-reports-second-quarter-2018-financial-results.htm
- ↑ "Financial Release - AbbVie". investors.abbvie.com.
- ↑ "Financial Release - AbbVie". investors.abbvie.com.
- ↑ "Financial Release - AbbVie". investors.abbvie.com.
- ↑ "Financial Release - AbbVie". investors.abbvie.com.
- ↑ "Financial Release - AbbVie". investors.abbvie.com.
- ↑ Mishra, Manas. http://www.abbottinvestor.com/static-files/9b97c378-cb63-402a-bbd9-cde779dc342e. Missing or empty
|title=
(help) - ↑ Abbott. "Abbott Reports Fourth-Quarter 2017 Results". www.prnewswire.com.
- ↑ Abbott. "Abbott Reports Fourth-Quarter 2016 Results". www.prnewswire.com.
- ↑ "Abbott Reports Fourth-Quarter 2015 Results".
- ↑ "Abbott Reports Fourth-Quarter 2014 Results".
- ↑ Abbott. "Abbott Reports Fourth-Quarter and Full-Year 2013 Results". www.prnewswire.com.
- ↑ "Abbott Reports Fourth-Quarter and Full-Year 2012 Results".
- ↑ "Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2011 Earnings - FiercePharma". www.fiercepharma.com.
- ↑ https://investor.lilly.com/static-files/8565700a-203e-4c17-8be3-748cc76e4762
- ↑ http://files.shareholder.com/downloads/LLY/5951368162x0x970018/15B962F7-AF5A-4FFA-BE13-42206D3A0820/Q4_2017_PressRelease.pdf
- ↑ "Lilly Reports Fourth-Quarter and Full-Year 2016 Results (NYSE:LLY)". investor.lilly.com.
- ↑ http://files.shareholder.com/downloads/LLY/5951368162x0x871993/5BE670A3-2B82-4876-8471-CA6BC3BD49F8/Lilly_Q4_2015_Press_Release.pdf
- ↑ http://files.shareholder.com/downloads/LLY/5951368162x0x806120/8637C572-31C4-402E-A179-5E107A5366B2/Q414_Lilly_Sales_and_Earnings_Press_Release.pdf
- ↑ http://files.shareholder.com/downloads/LLY/5951368162x0x721860/2DB60538-94FE-4E96-98D2-DA72CC301EA0/Q413%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
- ↑ http://files.shareholder.com/downloads/LLY/5951368162x0x631117/85679233-E13C-4FE7-9431-E97EFFDA6D5D/Q412%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
- ↑ http://files.shareholder.com/downloads/LLY/5951368162x0x538046/24A15621-7850-45EC-8E20-30535C3D9FC9/Q411_Lilly_Sales_and_Earnings_Press_Release.pdf
- ↑ http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&id=2360351
- ↑ "Amgen Reports Fourth Quarter And Full Year 2017 Financial Results". www.amgen.com.
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY1NTQ1fENoaWxkSUQ9MzczMzk1fFR5cGU9MQ==&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjI2OTYzfENoaWxkSUQ9MzI5ODc3fFR5cGU9MQ==&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTc0NTMzfENoaWxkSUQ9Mjc3NjczfFR5cGU9MQ==&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM3Nzc3fENoaWxkSUQ9MjI2ODE2fFR5cGU9MQ==&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDk5NjQxfENoaWxkSUQ9NTM5NDU4fFR5cGU9MQ==&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTM0MzEzfENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ https://www.businesswire.com/news/home/20180726005150/en/Bristol-Myers-Squibb-Reports-Quarter-Financial-Results
- ↑ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results". investors.bms.com.
- ↑ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results - BMS Newsroom". news.bms.com.
- ↑ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results - BMS Newsroom". news.bms.com.
- ↑ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results - BMS Newsroom". news.bms.com.
- ↑ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results - BMS Newsroom". news.bms.com.
- ↑ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/Bristol-Myers-Squibb-2012AR-lr.pdf
- ↑ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/BristolMyersSquibb-2011-AnnualReport.pdf
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDA4OTU2fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636680582523475446
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzk3OTQ3fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636534633626809804
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzc2MjEyfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636292722140277375
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzI4OTExfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=635944333723565434
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mjc3NTQ3fENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjI3MDc1fENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTc2OTgyfENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTMxNzQ1fENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ https://www.astrazeneca.com/content/dam/az/PDF/2018/h1-2018/H1%202018%20Results%20announcement.pdf
- ↑ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf
- ↑ https://www.astrazeneca.com/content/dam/az/PDF/Full_year_and_q4_2016_results/Full_Year_and_Q4_2016_Results_announcement.pdf
- ↑ "Full-Year and Q4 2015 Results". www.astrazeneca.com.
- ↑ "AstraZeneca PLC fourth quarter and full year results 2014". www.astrazeneca.com.
- ↑ "AstraZeneca PLC fourth quarter and full year results 2013 - AstraZeneca". www.astrazeneca.com.
- ↑ "AstraZeneca PLC Fourth quarter and full year results 2012". www.astrazeneca.com.
- ↑ "AstraZeneca PLC Fourth quarter and full year results 2011". www.astrazeneca.com.
- ↑ http://www.tevapharm.com/news/teva_reports_second_quarter_2018_financial_results_08_18.aspx
- ↑ "Teva Reports 2017 Full Year and Fourth Quarter Financial Results".
- ↑ http://www.tevapharm.com/news/teva_reports_full_year_and_fourth_quarter_2016_financial_results_02_17.aspx
- ↑ http://www.tevapharm.com/news/teva_reports_full_year_2015_and_fourth_quarter_financial_results_02_16.aspx
- ↑ "Teva Reports Fourth Quarter and Full Year 2014 Results". www.tevapharm.com.
- ↑ http://www.tevapharm.com/news/teva_reports_fourth_quarter_and_full_year_2013_results_02_14.aspx
- ↑ http://www.tevapharm.com/news/teva_reports_fourth_quarter_and_full_year_2012_results_02_13.aspx
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTI2NDkwfENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ "Boehringer Ingelheim 2017 Annual Report" (PDF). www.boehringer-ingelheim.com.
- 1 2 3 4 5 6 "Boehringer Ingelheim total revenue 2007-2017 - Statistic". Statista.
- ↑ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2018-q1/en/2018-Q1-Report-EN.pdf
- ↑ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2017-q4/en/2017-Q4-Report-EN.pdf
- ↑ http://ar2016.merckgroup.com/sites/default/files/downloads/en/merck_annual_report_2016.pdf
- ↑ http://ar2015.emdgroup.com/sites/default/files/downloads/emd/Merck_GB2015_EN.pdf
- ↑ http://ar2014.merckgroup.com/sites/default/files/downloads/en/Merck_GB2014_EN.pdf
- ↑ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2013-q4/en/2013-AR-EN.pdf
- ↑ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2012-q4/en/2012-AR-EN.pdf
- ↑ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2011-q4/en/2011-Merck-Annual-Report-EN.pdf
- ↑ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2018/20180808_Financial%20statement_Q2%202018_UK.pdf
- ↑ "News details". www.novonordisk.com.
- ↑ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2017/20170202_Financial%20statement_FY%202016_UK.pdf
- ↑ Transcripts, SA (3 February 2016). "Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q4 2015 Results - Earnings Call Transcript".
- ↑ Transcripts, SA (30 January 2015). "Novo Nordisk's (NVO) CEO Lars Sorensen on Q4 2014 Results - Earnings Call Transcript".
- ↑ Transcripts, SA (31 January 2014). "Novo Nordisk A/S Management Discusses Q4 2013 Results - Earnings Call Transcript".
- ↑ Transcripts, SA (31 January 2013). "Novo Nordisk's CEO Discusses Q4 2012 Results - Earnings Call Transcript".
- ↑ http://www.novonordisk.co.uk/content/dam/Denmark/HQ/Commons/documents/Novo-Nordisk-AR-2011-en.pdf
- ↑ http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzI0NDZ8Q2hpbGRJRD02OTc4MDc=
- 1 2 3 https://www.allergan.com/news/news/thomson-reuters/allergan-reports-solid-finish-to-2017
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTczMDc2fENoaWxkSUQ9Mjc1MzEzfFR5cGU9MQ==&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM5MDk2fENoaWxkSUQ9MjI4NjI0fFR5cGU9MQ==&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTc3MTM2fENoaWxkSUQ9LTF8VHlwZT0z&t=1
- ↑ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDYwMzczfENoaWxkSUQ9NDg4Mzk1fFR5cGU9MQ==&t=1
- ↑ https://www.takeda.com/newsroom/newsreleases/2018/takeda-reports-fy2017-full-year-results-and-issues-fy2018-guidance/
- ↑ http://investors.shire.com/~/media/Files/S/Shire-IR/quarterly-reports/2018/second-quarter-july2018-presentation.pdf
- ↑ "Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017". www.shire.com.
- ↑ http://investors.shire.com/~/media/Files/S/Shire-IR/quarterly-reports/2017/full-year-2016-results.pdf
- ↑ http://investors.shire.com/~/media/Files/S/Shire-IR/annual-report-2015/shire-annual-report-2015.pdf
- ↑ http://investors.shire.com/~/media/Files/S/Shire-IR/events/year-2015/1fy-2014-earnings-presentation-final-12-feb-2015.pdf
- ↑ http://ar2013.shire.com/downloads/Shire_Annual_report_2013_financial_statements.pdf
- ↑ "Shire Delivers Strong 2012 Results and Reiterates Confidence in 2013". investors.shire.com.
- ↑ http://investors.shire.com/~/media/Files/S/Shire-IR/annual-interim-reports/year-2011/annualreport2010170311.pdf
- ↑ http://ir.celgene.com/releasedetail.cfm?ReleaseID=1073027
- ↑ http://investors.biogen.com/static-files/44a04b54-7322-4009-8dfb-08cf7a79b80a
- ↑ "Biogen's Spinraza: Great Launch, Rough Ride". 25 January 2018 – via www.bloomberg.com.
- ↑ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2016_on_Form_10K.pdf
- ↑ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2015_on_Form_10K.pdf
- ↑ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_2014_Annual_Report_Web.pdf
- ↑ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2013.pdf
- ↑ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2012.pdf
- ↑ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/2011ar.pdf
External links
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.